Please upgrade your browser.
Here's a sneak peek at something new we're launching later this month. It's a collaboration that will enable patients to help transform medicine in ways that could help researchers to speed new treatments from the bench to the bedside. Stay tuned!
Jennerex, Biotherapeutics, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of best-in-class targeted oncolytic immunotherapies for solid tumors, today announced that the United States Food and Drug Administration (FDA) granted orphan drug designation for Pexa-Vec (JX-594, pexastimogene devacirepvec) for the treatment of hepatocellular carcinoma (HCC, commonly referred to as liver cancer).
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announces that the Company's miRview® suite of oncology diagnostic assays will be highlighted in an "Industry Expert Theater Presentation" at the American Society of Clinical Oncologists (ASCO) 2013 Annual Meeting taking place from May 31-June 4 at McCormick Place Convention Center in Chicago.
Cholesterol-lowering statin drugs that are taken by millions of Americans might also improve survival from a type of kidney cancer called renal cell carcinoma, a new study suggests.
Robot-assisted surgery to remove kidney cancers has seen a rapid increase in use, and has both replaced and proven safer than laparoscopic procedures for the same purpose, according to a study by the Vattikuti Urology Institute at Henry Ford Hospital in Detroit.
Eating plenty of fiber and fiber-rich foods may reduce the risk of kidney cancer among those at a healthy weight, suggests a large new study of almost half a million people. The study was published in the American Journal of Clinical Nutrition.
The number of urologists in the United States peaked in 2008 at 9852, and is now declining with serious consequences, especially in rural areas, said Raj Pruthi, MD, from the University of North Carolina at Chapel Hill. “We think this is a real problem.”
My focus in this 12-week series is to bring to light both the need for continued research in these fields, as well as highlight ways you can profit from the biggest current and upcoming players in each area.
Researchers at University of Texas Southwestern Medical Center Describe Findings in Pre-Trial Research
Herein, we report the development and validation of a tumorgraft model of renal cell carcinoma (RCC) and its application to the evaluation of an experimental drug.
Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era
Recent phase III studies of targeted agents for metastatic renal cell carcinoma (mRCC) have generated median survival estimates that far exceed those observed during the cytokine era. However, substantial population-based data does not exist to confirm this trend. We sought to determine whether survival has improved for patients with mRCC diagnosed in the era of targeted therapies, as compared to the era of immunotherapy.
|Powered by NeonCRM|